TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

T

Tizona Therapeutics

Status and phase

Active, not recruiting
Phase 1

Conditions

Cancer

Treatments

Drug: pembrolizumab
Drug: TTX-080
Drug: cetuximab

Study type

Interventional

Funder types

Industry

Identifiers

NCT04485013
TTX-080-001

Details and patient eligibility

About

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor) or cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies.

Full description

TTX-080 is a fully human mAb designed to block the interaction of HLA-G with its known ligands, ILT2 and ILT4 molecules. The Phase 1a was an open label, multicenter, dose escalation clinical trial to determine the safety, tolerability, MTD or OBD and the RP2D of TTX-080 when administered as a single agent. The Phase 1b is a dose expansion of TTX-080 monotherapy and in combination with either pembrolizumab or cetuximab in adult subjects with advanced refractory/resistant solid malignancies, including Head and Neck squamous cell carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Colorectal cancer (CRC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), and acral melanoma. Additionally, the study will seek to evaluate the pharmacokinetics and immunogenicity of TTX-080, and preliminary efficacy of TTX-080 as a monotherapy and in combination with pembrolizumab or cetuximab.

Enrollment

240 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Abbreviated Inclusion Criteria: 1. Subject with histological diagnosis of advanced/metastatic cancer 2. Age 18 years or older, is willing and able to provide informed consent 3. Evidence of measurable disease 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 AND life expectancy of at least 12 weeks Abbreviated Exclusion Criteria: 1. History of allergy or hypersensitivity to study treatment components. Subjects with a history of severe hypersensitivity reaction to any monoclonal antibody 2. Use of an investigational agent within 28 days prior to the first dose of study treatment and throughout the study 3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy 4. History of severe autoimmune disease 5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

240 participants in 9 patient groups

Phase 1a, Monotherapy Dose Escalation
Experimental group
Treatment:
Drug: TTX-080
Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)
Experimental group
Description:
Arm 1 will enroll subjects with advanced/metastatic, prior checkpoint inhibitor treated Head and Neck Squamous Cell Carcinoma (HNSCC)
Treatment:
Drug: TTX-080
Drug: pembrolizumab
Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)
Experimental group
Description:
Arm 2 will enroll subjects with advanced/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Treatment:
Drug: cetuximab
Drug: TTX-080
Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)
Experimental group
Description:
Arm 3 will enroll subjects with advanced/metastatic colorectal cancer (CRC)
Treatment:
Drug: TTX-080
Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), prior anti-EGFR therapy
Experimental group
Description:
Arm 4 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild-type colorectal cancer (CRC) who have progressed on a prior anti-EGFR therapy
Treatment:
Drug: cetuximab
Drug: TTX-080
Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC), no prior anti-EGFR therapy
Experimental group
Description:
Arm 5 will enroll subjects with advanced/metastatic MSI-L/MSS, KRAS wild type colorectal cancer (CRC) who have not received a prior anti-EGFR therapy
Treatment:
Drug: cetuximab
Drug: TTX-080
Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)
Experimental group
Description:
Arm 6 will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
Treatment:
Drug: TTX-080
Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)
Experimental group
Description:
Arm 7 will enroll subjects with advanced/metastatic prior checkpoint inhibitor treated non-small cell lung cancer (NSCLC)
Treatment:
Drug: TTX-080
Drug: pembrolizumab
Phase 1b, Dose Expansion: TTX-080 as monotherapy OR in combination with pembrolizumab
Experimental group
Description:
Arm 8: TTX-080 monotherapy: Advanced/metastatic, prior checkpoint inhibitor treated renal cell carcinoma with predominance of clear cell component Advanced/metastatic acral melanoma Arm 8: TTX-080 in combination with pembrolizumab: • Advanced/metastatic triple-negative breast cancer (estrogen and progesterone receptor negative and HER2 negative) who has received a prior checkpoint inhibitor
Treatment:
Drug: TTX-080
Drug: pembrolizumab

Trial contacts and locations

40

Loading...

Central trial contact

Tizona Therapeutics, Inc.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems